Avicanna Inc. Sponsors University of Calgary THC Dose Finding Clinical Trial
Avicanna Inc. is sponsoring a THC dose finding clinical trial to establish evidence-based dosing guidelines. This Phase I trial addresses a critical gap in cannabis medicine. The trial aims to optimize therapeutic outcomes while minimizing adverse…
Avicanna Sponsors University of Calgary THC Dose Finding Clinical Trial
Avicanna sponsors a THC dosing clinical trial at the University of Calgary to establish safe and effective therapeutic windows. This clinical trial aims to provide evidence-based dosing guidelines for THC. The study is essential for clinicians to improve…
CED Digest: 230 Items — March 15, 2026
This CED Digest highlights cannabis compounds fatty liver clinical relevance with 230 curated items for clinicians. CBD and CBG show potential therapeutic effects on fatty liver disease. These findings offer evidence-based insights for patient care in…
Study Finds No Link Between Smoking Cannabis and Cognitive Decline
Recent research on cannabis use and cognitive decline found no significant association in aging populations. This challenges previous assumptions about cannabis's neurotoxic effects. Clinicians can use this evidence to counsel patients more accurately…
Machine Learning Models Identify Key Predictors of Driving Under the Influence
Machine learning impaired driving risk models help identify key predictors of driving under the influence of alcohol or cannabis. These models enable clinicians to better assess patient risk and provide targeted counseling. Understanding these predictors…
Does Cannabis Use by Older Adults Accelerate Mental Decline? | Trending – Labroots
This article reviews cannabis use older adults mental decline and recent findings on cognitive safety. Evidence suggests no direct link between cannabis and accelerated mental decline in older adults. Clinicians should still assess individual risks and…
New Top Cannabis Regulator Sets Priorities In First Board Meeting
The new cannabis regulatory priorities focus on improving product safety and testing standards. These changes directly affect clinical practice and patient access. Clinicians must stay informed about evolving regulations to guide patients effectively.
Cannabinoids and Their Potential in Inflammatory and Metabolic Conditions
Cannabinoids inflammatory metabolic conditions research shows promise but requires cautious interpretation. Clinical efficacy in patient care remains uncertain without robust data. This article highlights the need for skepticism and further studies.
Georgia House Passes Bill to Expand Medical Cannabis Program
Georgia medical cannabis expansion will increase patient eligibility and require clinicians to update screening and dosing protocols. The new bill reflects evidence-based policy development. Providers should prepare for changes in clinical practice and…
Study Finds CBD and CBG May Counter Fatty Liver Disease
Emerging CBD CBG fatty liver disease research suggests these cannabinoids may improve liver metabolism and reduce lipid accumulation. This preclinical study highlights potential hepatoprotective effects. Clinicians should consider these findings…